News

Novel digital biomarkers to aid in the diagnosis and tracking of symptoms in patients with Parkinson’s Disease

July 6, 2021

Dr Rutger Zietsma – CEO at Manus Neurodynamica Ltd – and PD Dr Angela Deutschländer share their vision on earlier diagnosis and objective symptom tracking with the NeuroMotor PenTM Parkinson’s disease (PD) is a progressive neurological condition associated with dysfunction of the extrapyramidal system. The cardinal symptoms of PD are bradykinesia … Read more

ISO Certification of Quality Management System

June 17, 2021

Validates Manus as a medical device company allowing the Company to fully engage in commercial activities Edinburgh, UK – 17 June 2021: Manus Neurodynamica Limited (“Manus”), which develops and markets products and technologies for neuromotor assessment, announces that it has received ISO 13485:2016 certification following an assessment of its … Read more

£600k grant funding from Innovate UK To validate the NeuroMotor PenTM for screening of dementias and cognitive im-pairment

April 20, 2021

Edinburgh, UK – 20 April 2021: Manus Neurodynamica Limited (“Manus”), which develops and markets products and technologies for neuromotor assessment, has received £600,000 grant funding from Innovate UK, to optimise and validate the NeuroMotor PenTM (NMP) for screening of dementias and cognitive impairment, over a two-year project. Only around … Read more

Ex-Siemens Business Development Manager joins Manus

March 18, 2021

Manus Neurodynamica Limited Ex-Siemens Business Development Manager joins Manus Director of Commercial Growth appointed to execute sales and marketing strategy Edinburgh, UK – 18 March 2021: Manus Neurodynamica Limited (“Manus”), which develops and markets products and technologies for neuromotor assessment, announces the appointment of Euan Donald as Director of … Read more

MANUS NEURODYNAMICA LIMITED NeuroMotor Pen™ Differentiates Parkinson’s from other tremors; Regulatory submission in the USA

February 16, 2021

Edinburgh, UK – 16 February 2021: Manus Neurodynamica Limited (“Manus”), which develops and markets products and technologies for neuromotor assessment, announces the results of a clinical study to validate the Manus system’s ability to distinguish Parkinson’s Disease (PD) from other movement disorders. The study was conducted at Northumbria Healthcare … Read more

MANUS NEURODYNAMICA LIMITED NeuroMotor Pen™ predictive of side effects of anti-psychotics

February 1, 2021

Edinburgh, UK – 1 February 2021: Manus Neurodynamica Limited (“Manus”), which develops and markets products and technologies for neuromotor assessment, announces the results of a clinical study to evaluate the utility of the Manus system in the assessment of the extrapyramidal adverse effects of antipsychotic drugs conducted in collaboration … Read more

Manus secures £1.2m to support launch of Parkinson’s Pen

January 25, 2021

Edinburgh, UK – Monday 25th January 2021:  Edinburgh medtech company Manus Neurodynamica Limited (“Manus”), has closed a £1.2M funding round to support the launch of its digital pen which provides an early warning of Parkinson’s disease and other neurological conditions. With this latest funding secured, Manus is rolling-out its NeuroMotor … Read more

£750,000 investment to support commercial roll-out of NeuroMotor PenTM

June 3, 2020

Manus Neurodynamica Limited £750,000 investment in Parkinson’s diagnostic Scottish funds to support commercial roll-out of NeuroMotor PenTM Edinburgh, UK – 3 June 2020:  Manus Neurodynamica Limited (“Manus”), which develops and markets products for neuromotor assessment, including the NeuroMotor PenTM– a platform technology that can diagnose Parkinson’s disease and other … Read more

Manus Manufacturing Agreement

January 18, 2020

Manus Neurodynamica Limited Writing instrument giant STABILO to make Manus’ diagnostic pen Edinburgh, UK – 18th January 2020: MANUS Neurodynamica Limited (“Manus”), which develops and markets products and technologies for neuromotor assessment, announces a five-year manufacturing and supply agreement with STABILO International GmbH (“STABILO”) for its digital pen. STABILO … Read more

Digital Health Society Summit “Connecting Digital Health & Data Initiatives in Europe” December 2019

December 17, 2019

Manus Neurodynamica and the NeuroMotor Pen were also presented at The Digital Health Society Summit – “Connecting Digital Health & Data Initiatives in Europe”. The event was a two-day forum about data-driven transformation of health and social care, and it took place in Helsinki, Finland, on December 12th, 2019. … Read more